SMA UK and Many Others Respond to NICE’s Consultation on Access to Risdiplam
23 June 2021
Our thanks to the many people we talked with who planned to make their own personal responses. These will powerfully echo the voices of those who responded to our surveys and spoke up at the committee meeting.
Together, we are calling for access for all for whom risdiplam is a clinically safe option.
You can read our consultation response (jointly with MDUK), by clicking on the link below.